PT  - JOURNAL ARTICLE
AU  - Bationo, Cédric S.
AU  - Lokossou, Virgil
AU  - Landier, Jordi
AU  - Sylla, Bry
AU  - Tougri, Gauthier
AU  - Ouedraogo, Boukary
AU  - Cissoko, Mady
AU  - Moiroux, Nicolas
AU  - Gaudart, Jean
TI  - Geo-epidemiology of Malaria in Burkina Faso, 2013-2018: a recent re-increase
AID  - 10.1101/2021.10.27.21265260
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.27.21265260
4099  - http://medrxiv.org/content/early/2021/10/28/2021.10.27.21265260.short
4100  - http://medrxiv.org/content/early/2021/10/28/2021.10.27.21265260.full
AB  - Background After a global decline, malaria cases re-increases have been shown recently.The aim of this analysis was to update the epidemiological facies of malaria in Burkina Faso (around 4% of malaria cases worldwide) by estimating weekly malaria incidences at health district levels, from 2013 to 2018, associated to environmental and meteorological factors.Methods Malaria cases and deaths weekly reports were extracted from the National Malaria Control Program for each health district from 2013 to 2018. Population data were extracted from the reports of the national statistics council. Environmental data were collected through remote sensing.After estimating incidence through time and space, trend was assessed by an additive decomposition of the incidence and malaria seasons of transmission was estimated by change point analysis (PELT algorithm).Incidence maps for each year of the study period were assessed to highlight spatial variability through years. Maps of rainfall, temperature, and vegetation (NDVI) were produced to characterize the health district environmental variability.Results In 2013, 775 cases /100,000 inhab.week were observed in average, and remain roughly constant until 2015. Malaria re-increased from 2016, reaching 2428 cases /100,000 inhab.week in 2018.From 2013 to 2016, two transmission periods were observed: low from January to July (included) and high from August to December (included).From 2017 to 2018, an intermediate transmission period from mid-November to early January intercalated between the low transmission period from mid-February to early June and the high transmission period from July to late DecemberFrom 2013 to 2015, the most affected districts were located in the center and central-eastern part of the country. From 2016 to 2018 all health districts, except those in the Sahel region, were affected with at least 45,000 cases per 100,000 persons/year. This south-to-north gradient was also observed with rainfall, temperature and NDVI.Conclusion Malaria incidences re-increased through years and across the country since 2016. But no modification of the environmental factor variability was observed during the same period, in time or space. The re-increase of malaria in Burkina Faso could be due to a real increase of the disease, or to a better access to diagnostic and cure, together with the development of the epidemiological information system.Competing Interest StatementThe authors have declared no competing interest.Funding StatementC.S.B. received a grant from the Revivre Developpement Endowment Fund through the NGO Prospective et Cooperation, as well as a French Government Grant through the French Embassy in Burkina Faso. The funding was also provided by Excellence Initiative of Aix Marseille University A*MIDEX. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analyzed in this study may be available from the last author on reasonable request.